Human Preadipocytes - Visceral (HPAs-v)

Cat.No.: CSC-C4009X

Species: Human

Source: Adipose

Cell Type: Preadipocyte

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C4009X
Description
Preadipocytes, found in adipose tissues throughout adulthood, can proliferate and differentiate into mature adipocytes based on energy balance, which in turn increases adipose tissue mass. In vitro studies show that preadipocytes from different tissues vary in lipid accumulation, expression of adipogenic transcription factors, and susceptibility to TNF-induced apoptosis. Furthermore, adipocyte differentiation is closely linked to various physiological and pathological processes, including fat metabolism, energy balance, obesity, diabetes, hyperlipidemia, and breast cancer.
Human Preadipocytes - Visceral (HPAs-v) from Cretive Bioarray are isolated from human visceral fat tissue. HPA-v are cryopreserved at passage one and delivered frozen. Each vial contains at least 0.5 x 10^6 cells in 1 ml volume. HPAs-v are negative for HIV-1, HBV, HCV, mycoplasma, bacteria, yeast and fungi. HPAs-v are guaranteed for further culture under conditions specified by Creative Bioarray.
Species
Human
Source
Adipose
Cell Type
Preadipocyte
Disease
Normal
Storage and Shipping
Store in liquid nitrogen and ship in dry ice.
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Human visceral preadipocytes (HPAs-v) are primary mesenchymal progenitor cells isolated from the stromal vascular fraction of omental adipose tissue. As non-immortalized, diploid cells derived directly from human donors, they retain the complete depot-specific molecular identity of intra-abdominal fat, offering a physiologically authentic system that is unconfounded by the species-dependent metabolic divergences inherent to rodent models.

The defining advantage of HPAs-v is their faithful recapitulation of the pathogenic hallmarks of visceral obesity: they exhibit high basal and catecholamine-stimulated lipolytic rates coupled with profound resistance to the anti-lipolytic action of insulin, thereby replicating the excessive free fatty acid flux that drives ectopic lipid deposition and hepatic insulin resistance. In parallel, they constitutively secrete a pro-inflammatory panel-including elevated IL-6, TNF-α, and MCP-1-while producing disproportionately low adiponectin, thus mirroring the chronic low-grade inflammation that characterizes visceral adipose tissue dysfunction.

HPAs-v display a uniquely heightened sensitivity to glucocorticoids due to abundant expression of the glucocorticoid receptor and the enzyme 11β-hydroxysteroid dehydrogenase type 1, making them an exquisite model for studying cortisol-driven central adipogenesis and its metabolic consequences. They are amenable to lentiviral gene delivery and siRNA-mediated knockdown, facilitating mechanistic gene-function analyses, and can be co-cultured with macrophages to dissect paracrine inflammatory crosstalk.

Endothelin-1 Stimulates the Growth of Visceral and Subcutaneous Human Preadipocytes

Endothelin-1 (ET-1) regulates adipogenesis and the endocrine activity of adipocytes in obesity. Human white adipocytes are central to energy storage and endocrine regulation. However, relatively little is known about the involvement of the ET-1 signaling pathway in the growth of human white preadipocytes (HWPs). Therefore, this study investigated the cellular signaling mechanisms in HWPs, focusing on the cellular and functional basis of the actions of ET-1.

In this study, signaling protein levels, cell proliferation, and the numbers of visceral HWPs were measured by immunoblotting and MTT, and trypan blue exclusion assays. Both ET type A receptor (ETAR) and ET type B receptor (ETBR) antagonists inhibited the ET-1-induced growth of visceral HWPs and the phosphorylation of AMPK, PKC, and STAT3 in these cells. The ETBR antagonist alone blocked the ET-1-induced phosphorylation of ERK and c-JUN. Pretreatment with specific inhibitors of AMPK, ERK, JNK, STAT3, and PKC prevented ET-1-induced cell proliferation and attenuated the phosphorylation of AMPK, ERK, c-JUN, STAT3, and PKC induced by ET-1. These distinct signaling pathways, along with the optimization of pathway-specific inhibitors, have potential implications for the future management of obesity and metabolic disorders.

ET-1 stimulated visceral HWP proliferation.

Fig. 1. ET-1 stimulated visceral HWP proliferation (Siao, An-Ci, et al., 2025).

ET-1 stimulated visceral HWP growth through the JNK/c-JUN pathway but not the p38 MAPK pathway.

Fig. 2. ET-1 stimulated visceral HWP growth through the JNK/c-JUN pathway (Siao, An-Ci, et al., 2025).

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products